LORAZEPAM INJECTION USP SOLUTION

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

LORAZEPAM

Beschikbaar vanaf:

SANDOZ CANADA INCORPORATED

ATC-code:

N05BA06

INN (Algemene Internationale Benaming):

LORAZEPAM

Dosering:

4MG

farmaceutische vorm:

SOLUTION

Samenstelling:

LORAZEPAM 4MG

Toedieningsweg:

INTRAMUSCULAR

Eenheden in pakket:

1 ML

Prescription-type:

Targeted (CDSA IV)

Therapeutisch gebied:

BENZODIAZEPINES

Product samenvatting:

Active ingredient group (AIG) number: 0110731004; AHFS:

Autorisatie-status:

APPROVED

Autorisatie datum:

2005-08-12

Productkenmerken

LORAZEPAM INJECTION USP _(lorazepam)_
_ _
Page 1 of 35
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
C/T
LORAZEPAM INJECTION USP
Lorazepam
Injection, 4 mg/mL, intravenous, intramuscular
USP
Anxiolytic – Sedative
Sandoz Canada Inc.
110 Rue de Lauzon
Boucherville, QC, Canada
J4B 1E6
Date of Initial Authorization:
JUN 6, 2001
Date of Revision:
JUL 18, 2023
Submission Control No.: 272297
LORAZEPAM INJECTION USP _(lorazepam)_
_ _
Page 2 of 35
RECENT MAJOR LABEL CHANGES
1 INDICATIONS, 1.2 Geriatrics
12/2021
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
12/2021
4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations
07/2023
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dosage and
Dosage Adjustment
07/2023
7 WARNINGS AND PRECAUTIONS
12/2021
7 WARNINGS AND PRECAUTIONS, Dependence/Tolerance
07/2023
7 WARNINGS AND PRECAUTIONS, 7.1.4 Geriatrics
12/2021
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................. 5
4
DOSAGE AND ADMINISTRATION
....................................................................